AMAG Pharmaceuticals, Inc. provided unaudited earnings guidance for the fourth quarter and full year of 2018. For the quarter, the company expected total revenues from continuing operations for the fourth quarter of 2018 to be between $85 million and $90 million. This includes Makena® (hydroxyprogesterone caproate injection) net product sales of between $46 million and $48 million, Feraheme and MuGard® net product sales of between $34 million and $36 million, and Intrarosa net product sales of between $5 million and $6 million. Operating loss of between $17 million and $27 million. For the year 2018, the company expected Total revenues from continuing operations are expected to be between $471 million and $476 million. This includes Makena net product sales of between $321 million and $323 million, Feraheme and MuGard net product sales of between $134 million and $136 million, and Intrarosa net product sales of between $15 million and $16 million. As a result of the sale of Cord Blood Registry® (CBR), which closed on August 6, 2018, CBR’s results have been excluded from the financial results. Operating loss of between $45 million and $55 million For the year 2019, the company expected total revenue of $365 million to $415 million, operating loss of $131 million to $101 million.